EDOXABAN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C24H30ClN7O4S
Molecular Weight	548.058
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)NC2=NC=C(Cl)C=C2)[C@@H](C1)NC(=O)C3=NC4=C(CN(C)CC4)S3

InChI

InChIKey=HGVDHZBSSITLCT-JLJPHGGASA-N

InChI=1S/C24H30ClN7O4S/c1-31(2)24(36)13-4-6-15(27-20(33)21(34)30-19-7-5-14(25)11-26-19)17(10-13)28-22(35)23-29-16-8-9-32(3)12-18(16)37-23/h5,7,11,13,15,17H,4,6,8-10,12H2,1-3H3,(H,27,33)(H,28,35)(H,26,30,34)/t13-,15-,17+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C24H30ClN7O4S
Molecular Weight	548.057
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/18624979

Edoxaban (DU-176b, trade names Savaysa, Lixiana) is a selective factor Xa inhibitor reduces thrombin generation and thrombus formation and is an orally bioavailable anticoagulant drug. It was developed by Daiichi Sankyo to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis and pulmonary embolism following 5-10 days of initial therapy with a parenteral anticoagulant.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Coagulation factor X 20 Target ID: CHEMBL244 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18096568	Inhibitor 8297		0.561 nM [Ki]

Conditions

Condition	Modality	Highest Phase	Product
Nonvalvular atrial fibrillation 4 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf	Preventing	Approved 8429	SAVAYSA Approved Use SAVAYSA is a factor Xa inhibitor indicated: To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) (1.1) Limitation of Use for NVAF SAVAYSA should not be used in patients with creatinine clearance (CrCL) > 95 mL/min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied (60 mg) (1.1) SAVAYSA is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant (1.2) 1.1 Reduction in the Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation SAVAYSA is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). Limitation of Use for NVAF SAVAYSA should not be used in patients with CrCL > 95 mL/min because of an increased risk of ischemic stroke compared to warfarin [see Dosage and Administration (2.1), Warnings and Precautions (5.1), Clinical Studies (14.1) Launch Date 2015
Deep vein thrombosis 12 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf	Primary	Approved 8429	SAVAYSA Approved Use SAVAYSA is a factor Xa inhibitor indicated: To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) (1.1) Limitation of Use for NVAF SAVAYSA should not be used in patients with creatinine clearance (CrCL) > 95 mL/min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied (60 mg) (1.1) SAVAYSA is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant (1.2) 1.1 Reduction in the Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation SAVAYSA is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). Limitation of Use for NVAF SAVAYSA should not be used in patients with CrCL > 95 mL/min because of an increased risk of ischemic stroke compared to warfarin [see Dosage and Administration (2.1), Warnings and Precautions (5.1), Clinical Studies (14.1) Launch Date 2015
Pulmonary embolism 18 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf	Primary	Approved 8429	SAVAYSA Approved Use SAVAYSA is a factor Xa inhibitor indicated: To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) (1.1) Limitation of Use for NVAF SAVAYSA should not be used in patients with creatinine clearance (CrCL) > 95 mL/min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied (60 mg) (1.1) SAVAYSA is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant (1.2) 1.1 Reduction in the Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation SAVAYSA is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). Limitation of Use for NVAF SAVAYSA should not be used in patients with CrCL > 95 mL/min because of an increased risk of ischemic stroke compared to warfarin [see Dosage and Administration (2.1), Warnings and Precautions (5.1), Clinical Studies (14.1) Launch Date 2015

C_max

Value	Dose	Analyte	Population
305 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20081065	60 mg 2 times / day multiple, oral dose: 60 mg route of administration: Oral experiment type: MULTIPLE co-administered:	EDOXABAN TOSYLATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
507 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20081065	90 mg 1 times / day multiple, oral dose: 90 mg route of administration: Oral experiment type: MULTIPLE co-administered:	EDOXABAN TOSYLATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
649 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20081065	120 mg 1 times / day multiple, oral dose: 120 mg route of administration: Oral experiment type: MULTIPLE co-administered:	EDOXABAN TOSYLATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
302 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20081065	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	EDOXABAN TOSYLATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
312 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20081065	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	EDOXABAN TOSYLATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
33.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20081065	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	EDOXABAN TOSYLATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
375 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20081065	90 mg single, oral dose: 90 mg route of administration: Oral experiment type: SINGLE co-administered:	EDOXABAN TOSYLATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
409 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20081065	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	EDOXABAN TOSYLATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
487 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20081065	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	EDOXABAN TOSYLATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
152 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20081065	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	EDOXABAN TOSYLATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
1805 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20081065	60 mg 2 times / day multiple, oral dose: 60 mg route of administration: Oral experiment type: MULTIPLE co-administered:	EDOXABAN TOSYLATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
2806 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20081065	90 mg 1 times / day multiple, oral dose: 90 mg route of administration: Oral experiment type: MULTIPLE co-administered:	EDOXABAN TOSYLATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
3682 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20081065	120 mg 1 times / day multiple, oral dose: 120 mg route of administration: Oral experiment type: MULTIPLE co-administered:	EDOXABAN TOSYLATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
1779 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20081065	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	EDOXABAN TOSYLATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1781 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20081065	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	EDOXABAN TOSYLATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
259 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20081065	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	EDOXABAN TOSYLATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2680 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20081065	90 mg single, oral dose: 90 mg route of administration: Oral experiment type: SINGLE co-administered:	EDOXABAN TOSYLATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2789 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20081065	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	EDOXABAN TOSYLATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4322 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20081065	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	EDOXABAN TOSYLATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
993 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20081065	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	EDOXABAN TOSYLATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
9.44 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20081065	60 mg 2 times / day multiple, oral dose: 60 mg route of administration: Oral experiment type: MULTIPLE co-administered:	EDOXABAN TOSYLATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
9.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20081065	90 mg 1 times / day multiple, oral dose: 90 mg route of administration: Oral experiment type: MULTIPLE co-administered:	EDOXABAN TOSYLATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
9.75 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20081065	120 mg 1 times / day multiple, oral dose: 120 mg route of administration: Oral experiment type: MULTIPLE co-administered:	EDOXABAN TOSYLATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
8.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20081065	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	EDOXABAN TOSYLATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
9.75 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20081065	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	EDOXABAN TOSYLATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
5.79 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20081065	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	EDOXABAN TOSYLATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
9.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20081065	90 mg single, oral dose: 90 mg route of administration: Oral experiment type: SINGLE co-administered:	EDOXABAN TOSYLATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
8.56 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20081065	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	EDOXABAN TOSYLATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
10.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20081065	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	EDOXABAN TOSYLATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
8.92 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20081065	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	EDOXABAN TOSYLATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
45% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206316s016lbl.pdf	unknown, unknown		EDOXABAN TOSYLATE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
120 mg 1 times / day steady, oral Highest studied dose Dose: 120 mg, 1 times / day Route: oral Route: steady Dose: 120 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/20081065	healthy, 18 - 55 years n = 9 Health Status: healthy Age Group: 18 - 55 years Sex: M Population Size: 9 Sources: https://pubmed.ncbi.nlm.nih.gov/20081065	Sources: https://pubmed.ncbi.nlm.nih.gov/20081065
150 mg single, oral Highest studied dose Dose: 150 mg Route: oral Route: single Dose: 150 mg Sources: https://pubmed.ncbi.nlm.nih.gov/20081065	healthy, 18 - 55 years n = 9 Health Status: healthy Age Group: 18 - 55 years Sex: M Population Size: 9 Sources: https://pubmed.ncbi.nlm.nih.gov/20081065	Sources: https://pubmed.ncbi.nlm.nih.gov/20081065
60 mg 2 times / day steady, oral Highest studied dose Dose: 60 mg, 2 times / day Route: oral Route: steady Dose: 60 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/20081065	healthy, 18 - 55 years n = 10 Health Status: healthy Age Group: 18 - 55 years Sex: M Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/20081065	Sources: https://pubmed.ncbi.nlm.nih.gov/20081065
750 mg single, oral Overdose Dose: 750 mg Route: oral Route: single Dose: 750 mg Sources: https://pubmed.ncbi.nlm.nih.gov/32944263	unknown, 57 years n = 1 Health Status: unknown Age Group: 57 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/32944263	Other AEs: Activated partial thromboplastin time prolonged... Other AEs: Activated partial thromboplastin time prolonged Sources: https://pubmed.ncbi.nlm.nih.gov/32944263
60 mg 1 times / day steady, oral Recommended Dose: 60 mg, 1 times / day Route: oral Route: steady Dose: 60 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf	Disc. AE: Ischemic stroke... AEs leading to discontinuation/dose reduction: Ischemic stroke Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf
60 mg 1 times / day steady, oral Recommended Dose: 60 mg, 1 times / day Route: oral Route: steady Dose: 60 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf	unhealthy n = 5417 Health Status: unhealthy Population Size: 5417 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf	Disc. AE: Bleeding... AEs leading to discontinuation/dose reduction: Bleeding (3.9%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf

AEs

AE	Significance	Dose	Population
Activated partial thromboplastin time prolonged		750 mg single, oral Overdose Dose: 750 mg Route: oral Route: single Dose: 750 mg Sources: https://pubmed.ncbi.nlm.nih.gov/32944263	unknown, 57 years n = 1 Health Status: unknown Age Group: 57 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/32944263
Ischemic stroke	Disc. AE	60 mg 1 times / day steady, oral Recommended Dose: 60 mg, 1 times / day Route: oral Route: steady Dose: 60 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf
Bleeding	3.9% Disc. AE	60 mg 1 times / day steady, oral Recommended Dose: 60 mg, 1 times / day Route: oral Route: steady Dose: 60 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf	unhealthy n = 5417 Health Status: unhealthy Population Size: 5417 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737 inhibitor 1587 inducer 781		inhibitor 1852 substrate 1217	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP2A6 707 CYP2B6 810 CYP2C8/9 44 CYP2C19 1478 CYP2E1 882 P-gp 1461 OAT1 599 OAT3 642 OCT1 512 OCT2 647 OATP1B1 788 OATP1B3 706 OATP1B2 6	P-gp 1537 FMO3 67 OCT2 355 CES1 22	CYP1A2 701 P-gp 257

Drug as perpetrator

Target	Modality	Activity
CYP1A2 1692	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf Page: 16.0	no
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf Page: 16.0	no
CYP2A6 739	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf Page: 16.0	no
CYP2B6 1001	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf Page: 16.0	no
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf Page: 16.0	no
CYP2C8/9 44	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf Page: 16.0	no
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf Page: 16.0	no
CYP2E1 970	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf Page: 16.0	no
CYP3A4 1925	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf Page: 16.0	no
CYP3A4 1925	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf Page: 16.0	no
OAT1 603	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf Page: 16.0	no
OAT3 644	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf Page: 16.0	no
OATP1B1 803	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf Page: 16.0	no
OATP1B2 6	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206316Orig1Orig2s000CrossR.pdf Page: 39.0	no
OATP1B3 715	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf Page: 16.0	no
OCT1 543	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf Page: 16.0	no
OCT2 648	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf Page: 16.0	no
P-gp 1650	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf Page: 16.0	no
P-gp 1650	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf Page: 16.0	no

Drug as victim

Target	Modality	Activity	Clinical evidence
CES1 22	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206316Orig1Orig2s000CrossR.pdf Page: 38.0	major
OCT2 355	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206316Orig1Orig2s000CrossR.pdf Page: 38.0	no
CYP2D6 1217	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206316Orig1Orig2s000PharmR.pdf Page: 286.0	unlikely
FMO3 67	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206316Orig1Orig2s000PharmR.pdf Page: 286.0	unlikely
CYP3A4 1737	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf Page: 15.0	yes
P-gp 1537	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf Page: 16.0	yes	yes (co-administration study) Comment: ketoconazole increased cmax of edoxaban 2x, auc 2x Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf Page: 16.0

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206316Orig1Orig2s000PharmR.pdf Page: 56.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:85973	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:85973
ChemicalBook	CB21518508	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB21518508
ChemicalBook	CB32593620	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB32593620
MolPort	MolPort-018-493-670	https://www.molport.com/shop/molecule-link/MolPort-018-493-670
ZINC	ZINC000043200832	http://zinc15.docking.org/substances/ZINC000043200832

PubMed

Title	Date	PubMed
New oral anticoagulants in atrial fibrillation.	2008 Jan	18096568
Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers.	2010 Jul	20081065
Factor Xa inhibitors: next-generation antithrombotic agents.	2010 Sep 9	20503967
Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.	2015 Mar	25682085
Overview of the new oral anticoagulants: opportunities and challenges.	2015 May	25792448
Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa.	2016 Jun	26620048

Patents

Sample Use Guides

In Vivo Use Guide

Nonvalvular Atrial Fibrillation: 60 mg taken orally once daily Deep Vein Thrombosis and Pulmonary Embolism: 60 mg taken orally once daily following 5 to 10 days of initial therapy with a parenteral anticoagulant. If a dose of is missed, the dose should be taken as soon as possible on the same day. Dosing should resume the next day according to the normal dosing schedule. The dose should not be doubled to make up for a missed dose.

Route of Administration: Oral

In Vitro Use Guide

In vitro, FXa inhibition, specificity and anticoagulant activities were examined. DU-176b (Edoxaban) inhibited FXa with Ki values of 0.561 nm for free FXa, 2.98 nm for prothrombinase, and exhibited >10 000-fold selectivity for FXa. In human plasma, DU-176b doubled prothrombin time and activated partial thromboplastin time at concentrations of 0.256 and 0.508 microm, respectively.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 17:50:42 GMT 2023` Edited by `admin` on `Sat Dec 16 17:50:42 GMT 2023`
Record UNII	NDU3J18APO
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

EDOXABAN

Official Name

English

N-(5-CHLOROPYRIDIN-2-YL)-N'-((1S,2R,4S)-4-(N,N-DIMETHYLCARBAMOYL)-2-(5-METHYL-4,5,6,7- TETRAHYDRO(1,3)THIAZOLO(5,4-C)PYRIDINE-2-CARBOXAMIDO)CYCLOHEXYL)OXAMIDE

Systematic Name

English

EDOXABAN [MART.]

Common Name

English

EDOXABAN [MI]

Common Name

English

EDOXABAN [USAN]

Common Name

English

Edoxaban [WHO-DD]

Common Name

English

DU-176

Code

English

ETHANEDIAMIDE, N1-(5-CHLORO-2-PYRIDINYL)-N2-((1S,2R,4S)-4- ((DIMETHYLAMINO)CARBONYL)- 2-(((4,5,6,7-TETRAHYDRO-5-METHYLTHIAZOLO(5,4-C)PYRIDIN-2-YL)CARBONYL)AMINO)CYCLOHEXYL)-

Common Name

English

edoxaban [INN]

Common Name

English

Classification Tree Code System Code

WHO-ATC

B01AF03